Sex: M
Vaccine: COVID19
Symptoms: Accidental exposure to product, Arthralgia, Device malfunction, Product dose omission issue, Skin plaque
Clinical narrative: PLAQUE SYMPTOMS QUADRUPLED; DID NOT PUNCTURE HIS SKIN AND MEDICATION STARTED RUNNING DOWN THE LEG; JOINT PAIN; MEDICATION STARTED RUNNING DOWN THE LEG; PATIENT HAVEN'T HAD IT SO LONG; This spontaneous report received from a patient concerned an adult of unspecified sex. Initial information processed along with follow up information received from Regulatory Agency on 13-JUN-2024. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (dose in series 1) (suspension for injection, intramuscular, batch number was not reported) dose, start therapy date were not reported (three years prior to the report) for covid-19 prophylaxis.  The batch number was not reported and has been requested. The patient received combination product guselkumab (solution for injection in pre-filled pen, subcutaneous, batch number: NIS5C.AB expiry: 30-SEP-2025) 100 mg, frequency, and therapy dates were not reported for an unspecified indication. The drug was associated with Medication error. Product constituent parts included one press (route of admin, lot, serial number, model number, UDI number, and expiration were not reported). No concomitant medications were reported.  The patient stated that three years ago when patient had the covid shot, the patient had the symptoms quadrupled the plaque and pain (dose series 1). It was reported that the patient could feel the joint pain (dose series 1) and was getting skin issues from not having it, little tiny plaques were starting to come up and the joint pain in intensifying because the patient haven't had it in so long. It was almost like the patient had to take longer to lower myself into a chair. Patient said when he pressed down on the autoinjector, he didn't feel the prick, it did not puncture the skin and medication started running down the leg. The medication was faulty. The action taken with covid-19 vaccine ad26.cov2.s, was not applicable for events did not puncture his skin and medication started running down the leg, plaque symptoms quadrupled, joint pain, medication started running down the leg and patient haven't had it so long  and  action taken with guselkumab was not applicable for events plaque symptoms quadrupled, joint pain  ; and action taken with guselkumab was not reported for events  did not puncture his skin and medication started running down the leg and medication started running down the leg . The outcome of the did not puncture his skin and medication started running down the leg, plaque symptoms quadrupled, joint pain, medication started running down the leg and patient haven't had it so long was not reported. This report was associated with PQC number 90000328436. This report was non-serious. The suspected product quality complaint has been confirmed to be 90000328436:voided:this record was generated for covid-19 vaccine and adverse events. there is no product quality issue described or allegation regarding product efficacy related to the vaccine. record #90000326867 captures report for tremfya. approval to void due to no pqc identified. based on the PQC evaluation/investigation performed.